ReproductiveFDA Approved

Cetrorelix (Cetrotide)

Subcutaneous injection

Overview

A synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose-dependent suppression of LH and FSH without the initial flare effect seen with GnRH agonists.

Mechanism of Action

Cetrorelix prevents premature LH surges during controlled ovarian stimulation in IVF, allowing precise timing of oocyte maturation and retrieval..

Research Summary & Key Findings

FDA-approved for prevention of premature LH surges in women undergoing controlled ovarian stimulation for IVF. GnRH antagonist protocols (including cetrorelix) associated with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) compared to agonist protocols. Flexible dosing allows initiation when lead follicle reaches 14 mm, reducing treatment burden.

Clinical Status

FDA Approved

Cetrorelix (Cetrotide) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection

Related Peptides in Reproductive

Find a Provider

Find a verified provider who offers Cetrorelix (Cetrotide) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cetrorelix (Cetrotide).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.